New Delhi [India], February 17 (ANI): A preliminary result of an Israeli study to evaluate the safety of EXO-CD24 exosomes in 30 enrolled patients with COVID-19 disease has claimed to show no serious adverse effects, and substantial improvement in respiratory rate, Professor Nadar Arber from